Advertisement

Klinische Pharmakokinetik der Neuroleptika: Ergebnisse und Probleme

  • U. Breyer-Pfaff
Conference paper
Part of the Tropon-Symposium book series (BAYERZNS, volume 2)

Zusammenfassung

Fast alle Neuroleptika sind basische amphiphile Substanzen, d. h. sie besitzen einen lipophilen und einen hydrophilen, nämlich geladenen Molekülanteil. Dies bestimmt ihr kinetisches Verhalten, das gekennzeichnet ist durch
  • leichte Penetration durch Lipidmembranen, dadurch hohe Resorptionsquote aus dem Darm

  • Anreicherung in Membranen, daher hohe Konzentration in parenchymatösen Organen, großes scheinbares Verteilungsvolumen

  • hohe Plasmaproteinbindung

  • geringe renale Ausscheidung in unveränderter Form

  • Elimination durch Stoffwechsel, hauptsächlich in der Leber

  • eingeschränkte orale Bioverfügbarkeit infolge Metabolismus beim ersten Durchgang durch Darmwand und Leber (“first-pass effect”).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Altamura AC, Curry SH, Montgomery S, Wiles DH (1985) Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients. Psychopharmacology 87: 30–33PubMedCrossRefGoogle Scholar
  2. Axelsson R, Märtensson E (1978) Relationship between serum concentrations of thioridazine and its main nonconjugated metabolites and clinical response in thioridazine-treated patients. Curr Ther Res 24: 232–242Google Scholar
  3. Bianchetti G, Zarifian E, Poirier-Littre MF, Morselli PL, Deniker P (1980) Influence of route of administration on haloperidol plasma levels in psychotic patients. Int J Clin Pharmacol Ther Toxicol 18: 324–327PubMedGoogle Scholar
  4. Bolvig Hansen L, Larsen NE (1977) Plasma concentrations of perphenazine and its sulphoxide metabolite during continuous oral treatment. Psychopharmacology 53: 127–130CrossRefGoogle Scholar
  5. Bolvig Hansen L, Larsen NE (1985) Therapeutic advantages of monitoring plasma concentrations of perphenazine in clinical practice. Psychopharmacology 87: 16–19CrossRefGoogle Scholar
  6. Bolvig Hansen L, Larsen NE, Gulmann N (1982) Dose-response relationships of perphenazine in the treatment of acute psychoses. Psychopharmacology 78: 112–115CrossRefGoogle Scholar
  7. Breyer-Pfaff U (1983) Klinische Pharmakokinetik der Neuroleptika. In: Langer G, Heimann H (Hrsg) Psychopharmaka. Grundlagen und Therapie. Springer, Wien New York, S 251–258Google Scholar
  8. Breyer-Pfaff U, Brinkschulte M, Rein W, Schied HW, Straube E (1983) Prediction and evaluation criteria in perazine therapy of acute schizophrenics. Pharmacokinetic data. Pharmacopsychiatria 16: 160–165PubMedCrossRefGoogle Scholar
  9. Casper R, Garver DL, Dekirmenjian H, Chang S, Davis JM (1980) Phenothiazine levels in plasma and red blood cells. Their relation to clinical improvement in schizophrenia. Arch Gen Psychiatry 37: 301–305PubMedCrossRefGoogle Scholar
  10. Chang SS, Javaid JI, Dysken MW, Casper RC, Janicak PG, Davis JM (1985) Plasma levels of fluphenazine during fluphenazine decanoate treatment in schizophrenia. Psychopharmacology 87: 55–58PubMedCrossRefGoogle Scholar
  11. Creese I, Snyder SH (1977) A simple and sensitive radioreceptor assay for antischizophrenic drugs in blood. Nature 270: 180–182PubMedCrossRefGoogle Scholar
  12. Curry SH (1968) Determination of nanogram quantities of chlorpromazine and some of its metabolites in plasma using gas-liquid chromatography with an electron capture detector. Anal Chem 40: 1251–1255PubMedCrossRefGoogle Scholar
  13. Curry SH, Whelpton R, de Schepper PJ, Vranckx S, Schiff AA (1979) Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man. Br J Clin Pharmacol 7: 325–331PubMedGoogle Scholar
  14. Dahl SG (1976) Pharmacokinetics of methotrimeprazine after single and multiple doses. Clin Pharmacol Ther 19: 435–442PubMedGoogle Scholar
  15. Dahl SG, Strandjord RE (1977) Pharmacokinetics of chlorpromazine after single and chronic dosage. Clin Pharmacol Ther 21: 437–448PubMedGoogle Scholar
  16. Davis JM, Ericksen SE, Hurt S, Chang SS, Javaid JI, Dekirmenjian H, Casper R (1985) Haloperidol plasma levels and clinical response: basic concepts and clinical data. Psychopharmacol Bull 21: 48–51PubMedGoogle Scholar
  17. Dysken MW, Javaid JI, Chang SS, Schaffer C, Shahid A, Davis JM (1981) Fluphenazine pharmacokinetics and therapeutic response. Psychopharmacology 73: 205–210PubMedCrossRefGoogle Scholar
  18. Extein I, Augusthy A, Gold MS, Pottash ALC, Martin D, Potter WZ (1982) Plasma haloperidol levels and clinical response in acute schizophrenia. Psychopharmacol Bull 18: 156–158PubMedGoogle Scholar
  19. Extein I, Pottash ALC, Gold MS (1983) Therapeutic window for plasma haloperidol in acute schizophrenic psychosis. Lancet I:1048–1049Google Scholar
  20. Forsman A, Öhman R (1976) Pharmacokinetic studies on haloperidol in man. Curr Ther Res 20: 319–336PubMedGoogle Scholar
  21. Forsman A, Öhman R (1977) Applied pharmacokinetics of haloperidol in man. Curr Ther Res 21: 396–411Google Scholar
  22. Garver DL, Hirschowitz J, Glicksteen GA, Kanter DR, Mavroidis ML (1984) Haloperidol plasma and red blood cell levels and clinical antipsychotic response. J Clin Psychopharmacol 4: 133–137PubMedCrossRefGoogle Scholar
  23. Goldstein SA, Van Vunakis H (1981) Determination of fluphenazine, related phenothiazine drugs and metabolites by combined high-performance liquid chromatography and radioimmunoassay. J Pharmacol Exp Ther 217: 36–43PubMedGoogle Scholar
  24. Hansen CE, Christensen TR, Elley J, Bolvig Hansen L (1976) Clinical pharmacokinetic studies of perphenazine. Br J Clin Pharmacol 3: 915–923Google Scholar
  25. Harris PQ, Brown SJ, Friedman MJ, Bacopoulos NG (1984) Plasma drug and homovanillic acid levels in psychotic patients receiving neuroleptics. Biol Psychiatry 19: 849–860PubMedGoogle Scholar
  26. Holley FO, Magliozzi JR, Stanski DR, Lombrozo L, Hollister LE (1983) Haloperidol kinetics after oral and intravenous doses. Clin Pharmacol Ther 33: 477–484PubMedCrossRefGoogle Scholar
  27. Jann MW, Ereshefsky L, Saklad SR (1985) Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokin 10: 315–333CrossRefGoogle Scholar
  28. Jorgensen A (1980) Pharmacokinetic studies in volunteers of intravenous and oral cis(Z)-flupentixol and intramuscular cis(Z)-flupentixol decanoate in Viscoleo. Eur J Clin Pharmacol 18: 355–360PubMedCrossRefGoogle Scholar
  29. Jorgensen A (1986) Metabolism and pharmacokinetics of antipsychotic drugs. Progr Drug Metab 9: 111–174Google Scholar
  30. Jorgensen A, Andersen J, Bjorndal N, Dencker SJ, Lundin C, Malm U (1982) Serum concentrations of cis(Z)-flupentixol and prolactin in chronic schizophrenic patients treated with flupentixol and cis(Z)-flupentixol decanoate. Psychopharmacology 77: 58–65PubMedCrossRefGoogle Scholar
  31. Knudsen P (1985) Chemotherapy with neuroleptics. Clinical and pharmacokinetic aspects with a particular view to depot preparations. Acta Psychiatr Scand 72 [Suppl 322]: 51–75CrossRefGoogle Scholar
  32. Knudsen P, Bolvig Hansen L, Auken G, Waehrens J, Hojholt K, Larsen NE (1985a) Perphenazine decanoate vs. perphenazine enanthate: Efficacy and side effects in a 6 week double-blind, comparative study of 50 drug monitored psychotic patients. Acta Psychiatr Scand 72 [Suppl 322]: 15–28CrossRefGoogle Scholar
  33. Knudsen P, Bolvig Hansen L, Hojholt K, Larsen NE (1985b) Long-term depot neuroleptic treatment with perphenazine decanoate I. Efficacy and side effects in a 12 month study of 42 drug monitored psychotic patients. Acta Psychiatr Scand 72 [Supp] 3221: 29–40CrossRefGoogle Scholar
  34. Ko GN, Korpi ER, Linnoila M (1985) On the clinical relevance and methods of quantification of plasma concentrations of neuroleptics. J Clin Psychopharmacol 5: 253–262PubMedCrossRefGoogle Scholar
  35. Magliozzi JR, Hollister LE, Arnold KV, Earle GM (1981) Relationship of serum haloperidol levels to clinical response in schizophrenic patients. Am J Psychiatry 138: 365–367PubMedGoogle Scholar
  36. May PRA, Van Putten T (1978) Plasma levels of chlorpromazine in schizophrenia. A critical review of the literature. Arch Gen Psychiatry 35: 1081–1087PubMedCrossRefGoogle Scholar
  37. May PRA, Van Putten T, Jenden DJ, Yale C, Dixon WJ (1981) Chlorpromazine levels and the outcome of treatment in schizophrenic patients. Arch Gen Psychiatry 38: 202–207PubMedCrossRefGoogle Scholar
  38. McEvoy JP, Stiller RL, Farr R (1986) Plasma haloperidol levels drawn at neuroleptic threshold doses: A pilot study. J Clin Psychopharmacol 6: 133–138PubMedCrossRefGoogle Scholar
  39. Miller DD, Hershey LA, Duffy JP, Abernethy DR, Greenblatt DJ (1984) Serum haloperidol concentrations and clinical response in acute psychosis. J Clin Psychopharmacol 4: 305–310PubMedCrossRefGoogle Scholar
  40. Möller HJ, Kissling W, Lang C, Doerr P, Pirke KM, Zerssen D von (1982) Efficacy and side effects of haloperidol in psychotic patients: oral versus intravenous administration. Am J Psychiatry 139: 1571–1575PubMedGoogle Scholar
  41. Moulin MA, Davy JP, Debruyne D et al. (1982) Serum level monitoring and therapeutic effect of haloperidol in schizophrenic patients. Psychopharmacology 76: 346–350PubMedCrossRefGoogle Scholar
  42. Neborsky RJ, Janowsky DS, Perel JM (1982) Red blood cell/plasma haloperidol ratios and antipsychotic efficacy. Psychiatr Res 6: 123–124CrossRefGoogle Scholar
  43. Pajerski J, Stiller R, Perel J (1982) Comparison of gas chromatography (GC) and radioimmunoassay (RIA) of haloperidol ( H) and applications in pharmacokinetic studies. Fed Proc 41: 1065Google Scholar
  44. Potkin SG, Shen Y, Zhou D, Pardes H, Shu L, Phelps B, Poland R (1985) Does a therapeutic window for plasma haloperidol exist? Preliminary Chinese data. Psychopharmacol Bull 21: 59–61PubMedGoogle Scholar
  45. Rivera-Calimlim L, Gift T, Nasrallah HA, Wyatt RJ, Lasagna L (1978) Correlation between plasma concentrations of chlorpromazine and clinical response. Commun Psychopharmacol 2: 215–222PubMedGoogle Scholar
  46. Rivera-Calimlim L, Hershey L (1984) Neuroleptic concentrations and clinical response. Ann Rev Pharmacol Toxicol 24: 361–386CrossRefGoogle Scholar
  47. Rubin RT, Forsman A, Heykants J, Öhman R, Tower B, Michiels M (1980) Serum haloperidol determinations in psychiatric patients. Comparison of methods and correlation with serum prolactin levels. Arch Gen Psychiatry 37: 1069–1074PubMedCrossRefGoogle Scholar
  48. Sakalis G, Chan TL, Sathananthan G, Schooler N, Goldberg S, Gershon S (1977) Relationships among clinical response, extrapyramidal syndrome and plasma chlorpromazine and metabolite ratios. Commun Psychopharmacol 1: 157–166PubMedGoogle Scholar
  49. Schaffer CB, Shahid A, Javaid JI, Dysken MW, Davis JM (1982) Bioavailability of intramuscular versus oral haloperidol in schizophrenic patients. J Clin Psychopharmacol 2: 274–277PubMedCrossRefGoogle Scholar
  50. Shvartsburd A, Dekirmenjian H, Smith RC (1983) Blood levels of haloperidol in schizophrenic patients. J Clin Psychopharmacol 3: 7–12PubMedCrossRefGoogle Scholar
  51. Smith RC, Baumgartner R, Misra CH, Mauldin M, Shvartsburd A, Ho BT, DeJohn C (1984a) Haloperidol. Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical v. radioreceptor plasma level assays. Arch Gen Psychiatry 41: 1044–1049PubMedCrossRefGoogle Scholar
  52. Smith RC, Baumgartner R, Ravichandran GK, Shvartsburd A, Schoolar JC, Allen P, Johnson R (1984b) Plasma and red cell levels of thioridazine and clinical response in schizophrenia. Psychiatr Res 12: 287–296CrossRefGoogle Scholar
  53. Swigar ME, Jatlow PI, Goicoechea N, Opsahl C, Bowers MB Jr (1984) Ratio of serum prolactin to haloperidol and early clinical outcome in acute psychosis. Am J Psychiatry 141: 1281–1283PubMedGoogle Scholar
  54. Taylor G, Houston JB, Schaffer J, Mawer G (1983) Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man. Br J Clin Pharmacol 15: 287–293PubMedGoogle Scholar
  55. Van Putten T, May PRA, Jenden DJ (1981) Does a plasma level of chlorpromazine help? Psychol Med 11: 729–734PubMedCrossRefGoogle Scholar
  56. Van Putten T, Marder R, May PRA, Poland RE, O’Brien RP (1985) Plasma levels of haloperidol and clinical response. Psychopharmacol Bull 21: 69–72PubMedGoogle Scholar
  57. Wiesel FA, Alfredsson G, Ehrnebo M, Sedvall G (1980) The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects. Eur J Clin Pharmacol 17: 385–391PubMedCrossRefGoogle Scholar
  58. Wiles DH, Gelder MG (1979) Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injection of fluphenazine decanoate. Br J Clin Pharmacol 8: 565–570PubMedGoogle Scholar
  59. Wistedt B, Jorgensen A, Wiles D (1982) A depot neuroleptic withdrawal study. Plasma concentration of fluphenazine and flupenthixol and relapse frequency. Psychopharmacology 78: 301–304PubMedCrossRefGoogle Scholar
  60. Wode-Helgodt B, Alfredsson G (1981) Concentrations of chlorpromazine and two of its active metabolites in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of chlorpromazine. Psychopharmacology 73: 55–62PubMedCrossRefGoogle Scholar
  61. Wode-Helgodt B, Borg S, Fyrö B, Sedvall G (1978) Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of chlorpromazine. Acta Psychiatr Scand 58: 149–173PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • U. Breyer-Pfaff

There are no affiliations available

Personalised recommendations